Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marr...
Wedbush has initiated Imago BioSciences ( NASDAQ: IMGO ) with an outperform rating saying that its candidate bomedemstat could transform the treatment of myeloproliferative neoplasms. The firm has a $25 price target (~51% upside based on Thursday's close) Analyst Rober...
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc . (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone ma...
Imago BioSciences press release ( NASDAQ: IMGO ): Q2 GAAP EPS of -$0.41 beats by $0.09 . As of June 30, 2022, Imago had cash, cash equivalents and short-term investments of $190.0 million, compared to $217.4 million as of December 31, 2021. Based on current operati...
- Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia (ET) Presented at European Hematology Association (EHA) Meeting 2022 - - Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis Presented at EHA 2022 - ...
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc . (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone mar...
Announcing new data from a Phase 2 trial in essential thrombocythemia (ET), the clinical-stage biotech Imago BioSciences (NASDAQ:IMGO) said on Friday that 81% of patients treated with its lead asset bomedemstat for more than 24 weeks achieved a durable response. Data were part of a presentati...
- As of the data cutoff date of 29 April 2022, in addition to improvements in the standard metrics of spleen volume reduction and symptom scores, long term treatment with bomedemstat showed: 52% had reductions in mutant allele frequencies, including ASXL1 85% of evaluabl...
- The study completed enrollment with 73 patients in April 2022 - - As of the data cutoff of 29 April 2022, bomedemstat demonstrated durability of response with 81% of patients achieving normalized platelet counts for at least 12 weeks - - 58% of patients treated with bo...
SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced...
News, Short Squeeze, Breakout and More Instantly...
Imago BioSciences Inc. Company Name:
IMGO Stock Symbol:
NASDAQ Market:
Imago BioSciences Inc. Website:
NEW YORK, NY / ACCESSWIRE / December 27, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Imago BioSciences, Inc. (NASDAQ: IMG...
NEW YORK, NY / ACCESSWIRE / December 23, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Lakeland Bancorp, Inc. (NASDAQ:LBAI)...